Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1Bronchial Neoplasms 1

Interventions

Carboplatin 8Pemetrexed 3Paclitaxel 3durvalumab 2atezolizumab 2Nivolumab 2Ipilimumab 2Cisplatin 2Bevacizumab 2zipalertinib 1toripalimab 1sotorasib 1sitravatinib 1sintilimab 1pembrolizumab 1necitumumab 1demcizumab 1ceralasertib 1cemiplimab 1camrelizumab 1apatinib 1aflibercept 1Toll-Like Receptor 1 1Radiotherapy 1Omacor 1Gemcitabine 1Etoposide 1Erlotinib Hydrochloride 1Diarylheptanoids 1Diagnostic Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Diseases × Toll-Like Receptor 1 × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡